[go: up one dir, main page]

WO2007137135A3 - Rotenone analogs: method of preparation and use - Google Patents

Rotenone analogs: method of preparation and use Download PDF

Info

Publication number
WO2007137135A3
WO2007137135A3 PCT/US2007/069178 US2007069178W WO2007137135A3 WO 2007137135 A3 WO2007137135 A3 WO 2007137135A3 US 2007069178 W US2007069178 W US 2007069178W WO 2007137135 A3 WO2007137135 A3 WO 2007137135A3
Authority
WO
WIPO (PCT)
Prior art keywords
rotenone
analogs
preparation
present
tracers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/069178
Other languages
French (fr)
Other versions
WO2007137135A2 (en
Inventor
James P O'neil
Brocklin Henry F Van
Nandanan Erathodiyil
Andrew R Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2007137135A2 publication Critical patent/WO2007137135A2/en
Publication of WO2007137135A3 publication Critical patent/WO2007137135A3/en
Priority to US12/273,509 priority Critical patent/US8551448B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides rotenone analogs and methods of making and using them. Labeled with single photon and positron emitting isotopes, the rotenone analogs of the present invention are useful in, for example, clinical imaging applications as tracers to measure cardiac blood flow and detect regions of ischemia.
PCT/US2007/069178 2006-05-18 2007-05-17 Rotenone analogs: method of preparation and use Ceased WO2007137135A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/273,509 US8551448B2 (en) 2006-05-18 2008-11-18 Rotanone analogs: method of preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80133206P 2006-05-18 2006-05-18
US60/801,332 2006-05-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/273,509 Continuation US8551448B2 (en) 2006-05-18 2008-11-18 Rotanone analogs: method of preparation and use

Publications (2)

Publication Number Publication Date
WO2007137135A2 WO2007137135A2 (en) 2007-11-29
WO2007137135A3 true WO2007137135A3 (en) 2008-04-03

Family

ID=38724021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069178 Ceased WO2007137135A2 (en) 2006-05-18 2007-05-17 Rotenone analogs: method of preparation and use

Country Status (1)

Country Link
WO (1) WO2007137135A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102336764B (en) * 2011-06-21 2013-10-30 兰州大学 Spin-labeling rotenone oxime ester, its preparation method and application
CA2839351C (en) * 2011-07-13 2015-11-24 Nordion (Canada) Inc. Radiolabelled rotenone derivatives and their use in spect imaging
KR101422189B1 (en) * 2012-10-24 2014-07-22 한국원자력연구원 Phamarceutical compositions containing rotenone derivatives as an active ingredient for the prevention and treatment of obesity
CN103044440B (en) * 2012-12-31 2015-11-18 深圳市华农生物工程有限公司 A kind of Critical extraction method for rotenone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086476A1 (en) * 2002-04-08 2003-10-23 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086476A1 (en) * 2002-04-08 2003-10-23 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds

Also Published As

Publication number Publication date
WO2007137135A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2008010227A3 (en) Imaging protocols
GB0718967D0 (en) Peptide imaging agents
WO2007010534A3 (en) Imaging protocols
BR112015012014A2 (en) dual specific binding proteins penetrating the blood brain barrier (bbb)
IL201778A0 (en) Peptide imaging agents
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
WO2015073746A3 (en) 18f labeling of proteins using sortases
EP4374924A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2007109227A3 (en) Slit-slat collimation
MX2013010012A (en) Radiolabelled octreotate analogues as pet tracers.
MY150757A (en) Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
WO2008033557A3 (en) Click chemistry-derived cyclic peptidomimetics as integrin markers
MY163136A (en) Peptide radiotracer compositions
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
DE502007005902D1 (en) -METHYL-19-NOR-20-SPIROX-4-EN-3-ONE), as well as the PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
WO2007137135A3 (en) Rotenone analogs: method of preparation and use
WO2009134405A3 (en) Substrate based pet imaging agents
WO2009045535A3 (en) Fluorine-18 derivative of dasatinib and uses thereof
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
WO2008133730A3 (en) Labeled rotenone analogs
FI3058960T3 (en) Diagnostic agent for therapeutic effect on cancer
WO2012040138A3 (en) Choline analogs as radiotracer
PH12013501017A1 (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
WO2008151003A3 (en) Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07783894

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07783894

Country of ref document: EP

Kind code of ref document: A2